• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

July 9, 2025 By Sean Whooley

Breakthrough T1D Mattel Barbie T1D (1)
The new Barbie doll that gives visibility to the type 1 diabetes community. [Image courtesy of Breakthrough T1D/Mattel]
Breakthrough T1D (formerly JDRF) and Mattel announced a partnership to debut the first Barbie doll with type 1 diabetes (T1D).

They say the global collaboration reflects a shared commitment to ensure that people with T1D are “seen, heard and empowered.” It marks another initiative aiming to bring visibility to diabetes, following Insulet and Marvel’s launch of a new superhero with diabetes.

Breakthrough T1D and Mattel introduced their Barbie doll at the Breakthrough T1D 2025 Children’s Congress. They say they created the doll with input from the community to ensure the full representation of the lived experience of T1D.

Features include a blue polka dot top and skirt that reflect the global symbols representing diabetes awareness. The doll has an insulin pump and continuous glucose monitor (CGM). To keep the CGM in place. she has pink, heart-shaped medical tape. Her phone displays a CGM app for tracking blood sugar, and her purse allows her to carry her T1D supplies.

“Visibility matters for everyone facing type 1 diabetes,” said Emily Mazreku, director of marketing strategy at Breakthrough T1D. “As a mom living with T1D, it means everything to have Barbie helping the world see T1D and the incredible people who live with it.”

Filed Under: Diabetes, Featured Tagged With: Breakthrough T1D, Juvenile Diabetes Research Foundation (JDRF)

IN CASE YOU MISSED IT

  • MiniMed completes split from Medtronic
  • Insulet’s Omnipod Discover data platform begins full US rollout
  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS